

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 67041

Title: Hemorrhagic pericardial effusion following treatment with infliximab: A case report and literature review

Reviewer's code: 03034605

Position: Editorial Board

Academic degree: MBBS, MCh

Professional title: Chief Doctor, Surgeon

Reviewer's Country/Territory: India

Author's Country/Territory: China

Manuscript submission date: 2021-05-06

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-05-06 12:44

Reviewer performed review: 2021-05-10 01:52

Review time: 3 Days and 13 Hours

| | |
|---------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Language quality | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Re-review | <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |
| Peer-reviewer statements | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

The authors have presented an interesting case of infliximab induced hemorrhagic pericardial effusion. I have following comments regarding the manuscript: 1. Please mention whether the patient had any history of chest trauma or cardiac procedure. 2. Please mention the platelets count and coagulation profile of the patient. 3. Please mention the duration of the follow up. 4. Please discuss the pathogenesis of infliximab therapy induced pericardial effusion. 5. Please revise the table 1. The pericardial complications mentioned in Table 1 can be listed in one column. Please also mention the clinical presentation, timing of presentation after starting infliximab therapy, treatment given to the patients and the final outcome. All these findings of the previously reported cases should be discussed and compared with the index case in the Discussion section. 6. Please relocate the first line of Discussion at an appropriate place within the text of Discussion.

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 67041

Title: Hemorrhagic pericardial effusion following treatment with infliximab: A case report and literature review

Reviewer's code: 03849273

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Japan

Author's Country/Territory: China

Manuscript submission date: 2021-05-06

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-05-09 00:36

Reviewer performed review: 2021-05-12 07:17

Review time: 3 Days and 6 Hours

| | |
|---------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Language quality | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Re-review | <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |
| Peer-reviewer statements | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

I reviewed the manuscript `` title; Hemorrhagic pericardial effusion following treatment with infliximab: A case report and literature review.`` with great pleasure. In this manuscript, the authors describe the rare case complicated with hemorrhagic pericardial effusion due to the adverse effect of infliximab. This case is interesting, however, I could not see at the Figure because not attached Figure in this manuscript.